<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866134</url>
  </required_header>
  <id_info>
    <org_study_id>ERAS-007-01</org_study_id>
    <nct_id>NCT04866134</nct_id>
  </id_info>
  <brief_title>A Study of ERAS-007 in Patients With Advanced or Metastatic Solid Tumors</brief_title>
  <acronym>HERKULES-1</acronym>
  <official_title>A Phase 1b/2, Open-label, Multi-center Study of ERAS-007 in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasca, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasca, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the safety and tolerability of ERAS-007 monotherapy administered once weekly&#xD;
           (QW) and twice daily-once weekly (BID-QW).&#xD;
&#xD;
        -  To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007&#xD;
           monotherapy administered BID-QW.&#xD;
&#xD;
        -  To characterize the pharmacokinetic (PK) profile of ERAS-007 monotherapy.&#xD;
&#xD;
        -  To determine the optimal dose and schedule of ERAS-007 monotherapy.&#xD;
&#xD;
        -  To evaluate antitumor activity of ERAS-007 in various solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2, open-label, multicenter clinical study of ERAS-007 monotherapy&#xD;
      administered either QW or BID-QW. The monotherapy RD on a weekly schedule has been determined&#xD;
      to be 250 mg QW in a previous study. The dose escalation phase of this study will test&#xD;
      ERAS-007 monotherapy administered BID-QW in participants with any solid tumor. In parallel,&#xD;
      the dose expansion phase of this study will test ERAS-007 monotherapy administered at the RD&#xD;
      of 250 mg QW in participants with advanced or metastatic solid tumors harboring specific&#xD;
      molecular alterations. Once sufficient safety and PK data are available from the BID-QW dose&#xD;
      escalation phase, the Sponsor will then determine the optimal dose and schedule of ERAS-007&#xD;
      administered as a monotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate safety and tolerability of escalating doses of ERAS-007 BID-QW</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Based on adverse events observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Based on adverse events observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Based on adverse events observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose (RD)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Based on adverse events observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Incidence and severity of treatment-emergent AEs and serious AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration (Cmax)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Maximum plasma concentration of ERAS-007</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to achieve Cmax (Tmax)</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Time to achieve maximum plasma concentration of ERAS-007</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Area under the plasma concentration-time curve of ERAS-007</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life</measure>
    <time_frame>Study Day 1 up to Day 29</time_frame>
    <description>Half-life of ERAS-007</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Based on assessment of radiographic imaging per RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Based on assessment of radiographic imaging per RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Based on assessment of radiographic imaging per RECIST version 1.1</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic assessment</measure>
    <time_frame>Assessed up to 24 months from time of first dose</time_frame>
    <description>Assessment of phosphorylated ERK (pERK) inhibition in isolated PBMCs or tumor tissue by immunoblot, IHC or immunofluorescence.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation (Part A): ERAS-007 Monotherapy, BID-QW dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERAS-007 monotherapy will be administered BID-QW in sequential ascending doses to participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Part B): ERAS-007 Monotherapy, QW dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERAS-007 monotherapy will be administered at 250 mg QW to participants with advanced or metastatic solid tumors that harbor specific molecular alterations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Part C): ERAS-007 Monotherapy, BID-QW dosing (if necessary)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depending on data generated from Part A, ERAS-007 monotherapy may be administered at the BID-QW RD to participants with advanced or metastatic solid tumors that harbor specific molecular alterations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERAS-007</intervention_name>
    <description>ERAS-007 will be administered orally as specified in Arm description.</description>
    <arm_group_label>Dose Escalation (Part A): ERAS-007 Monotherapy, BID-QW dosing</arm_group_label>
    <arm_group_label>Dose Expansion (Part B): ERAS-007 Monotherapy, QW dosing</arm_group_label>
    <arm_group_label>Dose Expansion (Part C): ERAS-007 Monotherapy, BID-QW dosing (if necessary)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years.&#xD;
&#xD;
          -  Willing and able to give written informed consent.&#xD;
&#xD;
          -  Have histologically or cytologically confirmed advanced or metastatic solid tumor with&#xD;
             a relevant molecular alteration (as applicable).&#xD;
&#xD;
          -  There is no available standard systemic therapy available for the patient's tumor&#xD;
             histology and/or molecular biomarker profile; or standard therapy is intolerable, not&#xD;
             effective, or not accessible; or patient has refused standard therapy.&#xD;
&#xD;
          -  Recovered from all toxicities associated with prior treatment to acceptable baseline&#xD;
             status.&#xD;
&#xD;
          -  Have ECOG performance status of 0 or 1 with an anticipated life expectancy of &gt; 12&#xD;
             weeks.&#xD;
&#xD;
          -  Willing to comply with all protocol-required visits, assessments, and procedures.&#xD;
&#xD;
          -  Able to swallow tablets.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving another study therapy or has participated in a study of an&#xD;
             investigational agent and received study therapy within 4 weeks of the first dose of&#xD;
             ERAS-007.&#xD;
&#xD;
          -  Received previous treatment with an ERK inhibitor.&#xD;
&#xD;
          -  Received prior antineoplastic therapy within &lt; 21 days or 5 half-lives, whichever is&#xD;
             shorter.&#xD;
&#xD;
          -  Received prior palliative radiation within 7 days of first dose of ERAS 007.&#xD;
&#xD;
          -  Received previous treatment with a MAPK inhibitor that resulted in discontinuation due&#xD;
             to unacceptable toxicity.&#xD;
&#xD;
          -  Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal&#xD;
             dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may&#xD;
             affect drug absorption.&#xD;
&#xD;
          -  Have any underlying medical condition, psychiatric condition, or social situation&#xD;
             that, in the opinion of the Investigator, would compromise study administration as per&#xD;
             protocol or compromise the assessment of AEs.&#xD;
&#xD;
          -  Are pregnant or breastfeeding or expecting to conceive or father children within the&#xD;
             projected duration of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Lin, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erasca Clinical Team</last_name>
    <phone>+1-858-465-6511</phone>
    <email>clinicaltrials@erasca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (HealthONE)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (Florida Cancer Specialists)</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (Tennessee Oncology)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 24, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ERK</keyword>
  <keyword>solid tumor</keyword>
  <keyword>advanced solid tumor</keyword>
  <keyword>metastatic solid tumor</keyword>
  <keyword>neoplasms</keyword>
  <keyword>solid malignancies</keyword>
  <keyword>MAPK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

